Shearman & Sterling advised Boston Scientific Corporation on its recommended offer to acquire BTG PLC. The transaction is valued at approximately $4.2 billion and is subject to receipt of required regulatory approvals and the approval of BTG’s shareholders and the U.K. court.

BTG, headquartered in the United Kingdom, develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals. 

The Team